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Hypertension
EPIDEMIOLOGY/POPULATION SCIENCE

Isolated Diastolic Hypertension in the IDACO
Study: An Age-Stratified Analysis Using 24-Hour
Ambulatory Blood Pressure Measurements
John W. McEvoy ,* Wen-Yi Yang ,* Lutgarde Thijs , Zhen-Yu Zhang , Jesus D. Melgarejo , José Boggia ,
Tine W. Hansen , Kei Asayama , Takayoshi Ohkubo , Eamon Dolan, Katarzyna Stolarz-Skrzypek, Sofia Malyutina,
Edoardo Casiglia , Lars Lind , Jan Filipovský , Gladys E. Maestre , Yan Li , Ji-Guang Wang , Yutaka Imai,
Kalina Kawecka-Jaszcz, Edgardo Sandoya , Krzysztof Narkiewicz , Eoin O’Brien, Thomas Vanassche, Jan A. Staessen ;
on behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO)
Investigators
ABSTRACT: The prognostic implications of isolated diastolic hypertension (IDH), as defined by 2017 American College of
Cardiology (ACC)/American Heart Association (AHA) guidelines, have not been tested using ambulatory blood pressure (BP)
monitor thresholds (ie, 24-hour mean systolic BP <125 mm Hg and diastolic BP ≥75 mm Hg). We analyzed data from 11 135
participants in the IDACO (International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes).
Using 24-hour mean ambulatory BP monitor values, we performed Cox regression testing independent associations of IDH
with death or cardiovascular events. Analyses were conducted in the cohort overall, as well as after age stratification (<50
years versus ≥50 years). The median age at baseline was 54.7 years and 49% were female. Over a median follow-up of
13.8 years, 2836 participants died, and 2049 experienced a cardiovascular event. Overall, irrespective of age, IDH on 24hour ambulatory BP monitor defined by 2017 American College of Cardiology/American Heart Association criteria was not
significantly associated with death (hazard ratio, 0.95 [95% CI, 0.79–1.13]) or cardiovascular events (hazard ratio, 1.14 [95%
CI, 0.94–1.40]), compared with normotension. However, among the subgroup <50 years old, IDH was associated with excess
risk for cardiovascular events (2.87 [95% CI, 1.72–4.80]), with evidence for effect modification based on age (P interaction
<0.001). In conclusion, using ambulatory BP monitor data, this study suggests that IDH defined by 2017 American College of
Cardiology/American Heart Association criteria is not a risk factor for cardiovascular disease in adults aged 50 years or older
but is a risk factor among younger adults. Thus, age is an important consideration in the clinical management of adults with
IDH. (Hypertension. 2021;78:1222–1231. DOI: 10.1161/HYPERTENSIONAHA.121.17766.) Data Supplement

•
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A

mbulatory blood pressure (BP) monitor (ABPM)
recordings are considered superior to office BP
recordings in quantifying cardiovascular disease
risk.1,2 This is because 24-hour ABPM provides multiple
recordings and gives a more precise estimate of physiological BP levels during normal activity than once-off

measurements obtained in the clinic. In addition, ABPM
recordings offer the opportunity to determine BP values
during sleep, which have been shown to impart prognostic information.3 Consequently, our understanding of
a given BP phenotype is incomplete without data from
24-hour ABPM studies.
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What Is New?

Summary

• Using 24-hour ambulatory blood pressure monitor
recordings, we found no statistically significant association between isolated diastolic hypertension (IDH)
by 2017 American College of Cardiology (ACC)/
American Heart Association (AHA) criteria and
increased risk for outcomes in the IDACO (International
Database on Ambulatory Blood Pressure in Relation to
Cardiovascular Outcomes) cohort overall.
• By contrast, when the cohort was stratified by age,
risk for cardiovascular events was higher among persons younger than 50 years who had IDH by 2017
ACC/AHA criteria; but was not increased among older
adults with IDH.

These 24-hour ambulatory blood pressure monitor
data confirm prior reports that IDH by the 2017 ACC/
AHA definition is not associated with events in adults
overall, irrespective of their age. Our IDACO data also
confirm the known association between IDH by the
2018 European Society of Cardiology definition and
events. As such, the 2018 European Society of Cardiology definition of IDH appears to be a stronger risk
factor for cardiovascular events than the 2017 ACC/
AHA definition. The null association between the 2017
ACC/AHA definition of IDH and events in adults over
50 years suggests that older adults with mild IDH
do not need treatment as long as systolic BP is controlled. However, our data also indicate that the 2017
ACC/AHA definition of IDH is not completely benign
for adults younger than 50 years. However, because
young adults are at low absolute risk for events, future
studies are needed to test whether pharmacological
treatment of IDH in younger persons is efficacious
and cost-effective. For now, lifestyle management is
indicated among persons with IDH.

What Is Relevant?
• Our data indicate that IDH by the 2017 ACC/AHA
definition is not benign for adults younger than 50
years. These 24-hour ambulatory blood pressure monitor data help to settle an open question raised in prior
registries using less rigorous recording of blood pressure, which indicated that age is an important consideration in the management of patients with IDH.

Nonstandard Abbreviations and Acronyms
ABPM
ambulatory BP monitor
ACC
American College of Cardiology
AHA
American Heart Association
BP
blood pressure
ICD
International Classification of Diseases
ICD-10
ICD, Tenth Revision
ICD-8
ICD, Eighth Revision
ICD-9
ICD, Ninth Revision
IDACO	International Database on Ambulatory
Blood Pressure in Relation to Cardiovascular Outcomes
IDH
isolated diastolic hypertension
ISH
isolated systolic hypertension

One such phenotype, isolated diastolic hypertension
(IDH), is less common than combined systolic-diastolic
hypertension or isolated systolic hypertension (ISH).4
However, depending on the definition applied, IDH can
be seen in ≥6% of the adult population.5 There are 2
definitions of IDH currently in widespread use; the 2018
European Society of Cardiology (ESC) guideline defines
IDH as diastolic BP ≥90 mm Hg and systolic BP <140
mm Hg,6 and the 2017 American College of Cardiology
(ACC)/American Heart Association (AHA) guideline

defines IDH as diastolic BP ≥80 mm Hg with a systolic
BP <130 mm Hg (note that both of these definitions
assume office measurement of BP).7
There have been conflicting reports on the association of IDH with adverse cardiovascular outcomes,
especially using the 2017 ACC/AHA definition.4,5,8-11
Analyses suggesting a modest association between
the ACC/AHA definition of IDH and events have come
from large clinical registries that comprised of routine
clinical recordings of BP, whereas analyses finding no
association have analyzed BP values obtained under
more rigorous research conditions.5,11,12 In addition, one
of the clinical registries reporting a modest association
between the ACC/AHA definition of IDH and events
demonstrated clear evidence for interaction on the
basis of age, with a stronger association between IDH
and events among young versus old participants.10 By
contrast, the null studies reported to date using standardized BP values obtained under rigorous research
conditions have found no interaction by age.5,11 To clarify this uncertainty, we studied cardiovascular outcomes
in the IDACO (International Database on Ambulatory
Blood Pressure in Relation to Cardiovascular Outcomes) cohort among participants with IDH that was
confirmed using 24-hour ABPM, focusing primarily on
the 2017 ACC/AHA definition. Analyses were conducted in the IDACO sample overall and after stratification based on age.
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METHODS
The IDACO database is not publicly available; however, the
authors declare that all supporting data are available within the
article (and its Data Supplement).

Study Population
Previous publications describe the IDACO database in more
detail.3,13,14 Participating population studies qualified for inclusion if office and ambulatory BP measures and cardiovascular
risk factors were available at baseline and if follow-up included
both fatal and nonfatal outcomes. Of 13 111 people included
in the database, we excluded 1976, either because they were
teenagers (<18 years) without events (n=493) or because they
had an ambulatory BP recording with fewer than 6 daytime or 3
nighttime readings (n=1483).15 Thus, the number of individuals
analyzed was 11 135. We did not exclude persons on antihypertensive therapy in the main analysis, although we excluded them
in a sensitivity analysis. The expanded methods section and
Table S1 in the Data Supplement provide detailed information
on the population sampling methods, timelines, and country of
recruitment. All of the included studies received ethical approval
from the responsible institutional review boards in their country
of origin and all participants provided written informed consent.

BP Measurement
Nurses or physicians obtained the conventional office BP clinical readings with standard auscultation using a mercury sphygmomanometer or with validated microphone or oscillometric
automated BP measurement devices (see Expanded Methods
in the Data Supplement). For ambulatory BP monitoring (Table
S2), portable monitors were programmed to obtain ambulatory
readings at 30-minute intervals throughout the whole day or at
intervals of 15 to 30 minutes during daytime and at intervals
ranging from 20 to 60 minutes during the nighttime.16 Daytime
readings ranged from 10 am to 8 pm in European and South
American countries and from 8 am to 6 pm in Asian countries.
The corresponding nighttime intervals ranged from midnight to
6 am in European and South American countries and from 10
pm to 4 am in Asian countries. The Expanded Methods section in
the Data Supplement further describes the collection of questionnaire and biochemical data.

Ascertainment of End Points
We ascertained vital status and the incidence of fatal and
nonfatal events from the appropriate sources in each country.14 All events were prespecified and coded according to the
International Classification of Diseases (ICD). The coprimary
end points were total mortality and a composite cardiovascular
event consisting of cardiovascular mortality (ICD-8 [ICD, Eighth
Revision], 390–448; ICD-9 [ICD, Ninth Revision], 390.0–459.9;
and ICD-10 [ICD, Tenth Revision], I00–I79 and R96), coronary
events (death from ischemic heart disease [ICD-8, 411–412;
ICD-9, 411 and 414; and ICD-10, I20 and I24–I25], sudden
death [ICD-8, 427.2 and 795; ICD-9, 427.5 and 798; and ICD10, I46 and R96], nonfatal myocardial infarction [ICD-8 or
ICD-9, 410 and ICD-10, I21-I22], and coronary revascularization), stroke (ICD-8 or ICD-9, 430–434 and 436; and ICD-10,
I60–I64 and I67–I68, not including transient ischemic attack),
and heart failure (ICD-8, 427.0, 427.1, 427.2, 428, 429, 519.1,
1224   November 2021

and 782.4, ICD-9, 429, and ICD-10, I50 and J81). Secondary
outcomes included each of the individual outcomes included
in the composite cardiovascular event end point. All outcomes
were validated against hospital files or medical records held by
participants’ primary care physicians or specialists. In analyses
of composite outcomes, we only considered the first event.

Statistical Analysis
We used the Kolmogorov-Smirnov test for assessing the normality of distributions. For comparison of means and proportions, we applied the large-sample Z test and Fisher exact test,
respectively. After stratification by cohort and sex, we interpolated
missing values of body mass index and serum cholesterol levels
from the regression slopes on age. In participants with unknown
status of smoking, drinking, antihypertensive treatment, diabetes,
or unknown history of cardiovascular disease, we set the indicator (dummy) variable to the cohort- and sex-specific mean of the
codes (0, 1). Missing values were interpolated for body mass index
(n=33), serum cholesterol level (n=806), smoking status (n=56),
drinking status (n=805), antihypertensive treatment (n=16), diabetes (n=5), and history of cardiovascular disease (n=1).
Our analysis modeled 4 categorical exposures: normotension, IDH, ISH, and combined systolic-diastolic hypertension.
Conversion of clinic BP thresholds to their respective ABPM
equivalents was performed as recommended in 2017 ACC/
AHA7 and in 2018 ESC hypertension guidelines.17 Specifically,
the 24-hour systolic/diastolic ABPM thresholds for a diagnosis of IDH were 125/75 mm Hg by AHA/ACC and 130/80
mm Hg by ESC criteria. Similarly, the nighttime systolic/diastolic
ABPM thresholds for a diagnosis of IDH were 110/65 mm Hg
by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC criteria.
We compared the cumulative incidence of the primary and
secondary outcomes by hypertension category, after adjusting
for age and sex. In multivariable-adjusted Cox regression, we
adjusted for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking
status, serum cholesterol level, antihypertensive drug intake,
diabetes, and history of cardiovascular disease. We checked
the proportional hazards assumption by the Kolmogorov-type
supremum test. We prespecified that all Cox regression analyses were conducted in the IDACO sample overall and after
stratification on the basis of age (<50 years versus ≥50 years)
and sex. In these stratified analyses, we tested for effect modification using multiplicative interaction terms.
Sensitivity analyses excluded individuals either on baseline
antihypertensive medications or those with a baseline history
of cardiovascular disease from the models. Finally, we also performed sensitivity analyses of our 4 main categorical exposures
with further adjustment for either systolic BP or for diastolic BP
as continuous covariables at baseline.
For the statistical analysis, we used SAS software, version
9.4. Statistical significance was a 2-tailed α of ≤0.05.

RESULTS
Characteristics of Participants
The study sample analyzed (n=11 135) included 5494
women (49.3%) and consisted of 6929 White Europeans (62.2%), 1887 Asians (17.0%), and 2319 South
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Primary Analyses on the Whole Study Population
Median follow-up was 13.8 years (5th–95th percentile
interval, 2.5–25.1 years). During 153 140 person-years

of follow-up, 2836 participants died (incidence rate of
18.5 per 1000 person-years) and 2049 experienced
a composite cardiovascular event (13.4 per 1000 person-years), overall. When applying the 2017 ACC/AHA
hypertension criteria, crude incidence rates (per 1000
person-years) for death and cardiovascular events were
12.0 and 7.8 among normotensive participants, 9.7
and 8.4 among those with IDH, 34.1 and 26.3 among
those with ISH, and 27.2 and 23.5 among participants
with combined hypertension. Age and sex-standardized
cumulative incidence curves, for both outcomes and
among each BP category, are presented in the Figure.
Using the 2017 ACC/AHA criteria for IDH, there was
no statistically significant crude excess in either mortality or cardiovascular events relative to the normal BP
category. However, IDH according to 2018 ESC criteria
was associated with an increased cumulative incidence
of cardiovascular events (but not death). Irrespective of
the guideline criteria applied, both ISH and combined
systolic-diastolic hypertension were associated with an
excess in death and cardiovascular events.

Table 1. Baseline Characteristics of Participants by Hypertension Categories According to 24-Hour
Ambulatory BP Thresholds in 2017 ACC/AHA Guidelines
Characteristic
N (%) of participants
European

Normotensive

Isolated diastolic

Isolated systolic

Combined
hypertension

5418

1129

1325

3263

3352 (61.9)

649 (57.5)

863 (65.1)

2065 (63.3)

Asian

999 (18.4)

140 (12.4)

209 (15.8)

539 (16.5)

South American

1067 (19.7)

340 (30.1)

253 (19.1)

659 (20.2)

Women

3239 (59.8)

485 (43.0)

599 (45.2)

1171 (35.9)

Current smoking

1430 (26.4)

331 (29.3)

317 (23.9)

944 (28.9)

Drinking alcohol

2422 (44.7)

569 (50.4)

755 (57.0)

2069 (63.4)

On antihypertensive treatment

671 (12.4)

152 (13.5)

407 (30.7)

1032 (31.6)

Diabetes

293 (5.4)

37 (3.3)

170 (12.8)

349 (10.7)

History of CVD

452 (8.3)

114 (10.1)

253 (19.1)

472 (14.5)

58.9 (12.7)

Mean (SD) characteristic
Age, y

48.6 (16.0)

49.8 (12.6)

63.2 (14.6)

Body mass index, kg/m2

24.5 (4.1)

26 (4.2)

26.4 (4.7)

26.8 (4.3)

Serum total cholesterol, mmol/L

5.4 (1.1)

5.6 (1.2)

5.8 (1.2)

5.8 (1.2)

Blood pressure, mm Hg
  Conventional systolic

120.8 (16.6)

127.0 (14.5)

145.4 (23.6)

148.3 (22.4)

  Conventional diastolic

74.0 (9.1)

82.5 (9.2)

79.7 (10.5)

88.6 (11.4)

  24-h systolic

113.0 (6.9)

119.8 (4.0)

132.8 (8.0)

138.9 (11.3)

  24-h diastolic

67.7 (4.4)

78.3 (2.9)

70.7 (3.5)

83.3 (6.4)

  Daytime systolic

119.0 (8.5)

126.0 (6.3)

138.8 (9.7)

145.1 (12.3)

  Daytime diastolic

72.8 (5.7)

83.8 (4.7)

74.9 (5.2)

88.2 (7.4)

  Nighttime systolic

102.6 (8.3)

108.4 (7.3)

121.4 (12.5)

127.1 (14.6)

  Nighttime diastolic

58.9 (5.6)

68.1 (6.0)

62.7 (5.6)

74.0 (8.7)

The 24-h systolic/diastolic BP threshold for hypertension was 125/75 mm Hg by 2017 AHA/ACC criteria. Normotension refers to
those with both systolic/diastolic BPs lower than the cutoff values, whereas combined hypertension refers to those with both systolic/
diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those with only systolic
or diastolic BP elevated. Diabetes was a fasting plasma glucose level of ≥7.0 mmol/L or use of antidiabetic agents. ACC indicates
American College of Cardiology; AHA, American Heart Association; BP, blood pressure; and CVD, cardiovascular disease.
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Americans (20.8%). The median age at baseline was
54.7 years. Study participants included 3022 (27.3%)
smokers, 849 (7.6%) diabetics, and 1291 (11.6%) persons with a history of cardiovascular disease.
When applying the 2017 ACC/AHA hypertension
criteria using 24-hour ambulatory BP thresholds, our
sample comprised of 5418 (48.7%) participants with
normal BP values, 1129 (10.1%) with BP values meeting criteria for IDH, 1325 (11.9%) with BP values meeting criteria for ISH, and 3263 (29.3%) with combined
systolic-diastolic hypertension (Table 1). In comparison to
those with normal BP values, persons with IDH by ACC/
AHA criteria were numerically more likely to be South
American and male. Otherwise, the baseline characteristics of normotensive participants and those with IDH
appeared similar, as summarized in Table 1.

Age-Stratified Risk of Isolated Diastolic Hypertension
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Figure. Sex- and age-standardized cumulative incidence of total mortality and cardiovascular (CV) event by hypertensive categories.
Relative to normotension, isolated diastolic hypertension was not associated with increased risk of death or CV events when defined according
to 2017 American Heart Association/American College of Cardiology criteria. The 24-h systolic/diastolic ambulatory blood pressure (BP)
thresholds were 125/75 mm Hg by 2017 American Heart Association/American College of Cardiology (A and B) and 130/80 mm Hg by
2018 European Society of Cardiology (C and D) definitions. Normotension refers to those with both systolic/diastolic BPs lower than the
cutoff values, whereas combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated
systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. Tabulated data are the number of participants at
risk by hypertensive categories at 5-y intervals. P values show significance for comparison with the normotensive group.

In Cox regression analyses adjusted for cohort, sex, age,
body mass index, smoking status, alcohol drinking status, serum cholesterol levels, antihypertensive drug treatment use, diabetes, and history of cardiovascular disease
(Table 2), there was no independent association in the
sample overall between IDH by the 2017 ACC/AHA criteria and either death (hazard ratio, 0.95 [95% CI, 0.79–
1.13]) or cardiovascular events (hazard ratio, 1.14 [95% CI,
1226   November 2021

0.94–1.40]), compared with normotension. By contrast,
IDH by the 2018 ESC criteria was independently associated with risk for cardiovascular events (hazard ratio, 1.44
[95% CI, 1.12–1.85]; Table 2), but not death. Consistent
with the above-described excesses in crude events and
cumulative incidence rates, ISH and combined hypertension
by both sets of diagnostic criteria also demonstrated excess
adjusted risk in the Cox models, relative to normotension.
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Multivariable-Adjusted HR in Relation to Hypertension Categories by 24-Hour BP
Total mortality (n=2836)

Characteristic

HR (95% CI)

CV event (n=2049)
P value

HR (95% CI)

P value

2017 AHA/ACC criteria
Normotensive (n=5418)

Reference

Reference

Isolated diastolic (n=1129)

0.95 (0.79–1.13)

0.55

1.14 (0.94–1.40)

0.19

Isolated systolic (n=1325)

1.16 (1.04–1.29)

0.008

1.35 (1.18–1.53)

<0.001

Combined (n=3263)

1.35 (1.23–1.48)

<0.001

1.73 (1.55–1.93)

<0.001

2018 ESC criteria
Normotensive (n=7391)

Reference

Isolated diastolic (n=574)

1.22 (0.96–1.56)

0.11

1.44 (1.12–1.85)

Reference
0.004

Isolated systolic (n=1429)

1.36 (1.24–1.50)

<0.001

1.53 (1.37–1.71)

<0.001

Combined (n=1741)

1.39 (1.26–1.53)

<0.001

1.86 (1.66–2.08)

<0.001

The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions.
Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those
with both systolic/diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those
with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were
adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug
intake, history of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; CVD, CV disease; ESC, European Society of Cardiology; and HR, hazard ratio.

The above results were almost identical in analyses
of the subgroup of 8873 IDACO participants who were
not on BP medication at baseline (Table S3). Similarly,
when modeling participants on the basis of ABPM values at night, the results were again almost identical as for
24-hour readings, except that nocturnal IDH by the 2018
ESC criteria was no longer associated with cardiovascular events (results for full cohort in Table 3 and for the
subgroup not on BP medication at baseline in Table S4).

Further Sensitivity Analyses
In sensitivity analyses, we further adjusted the categorical
BP exposures (ie, IDH, ISH, and combined hypertension)
Table 3.

for either diastolic BP or systolic BP values as baseline
continuous covariables (Table S5 and Table S6). With further adjustment for diastolic BP as a continuous baseline
covariable, the results from the categorical analyses were
consistent with the main results presented in Tables 2
and 3. By contrast, with further adjustment for systolic
BP as a continuous baseline covariable, there was no
longer an association between IDH by the 2018 ESC
definition and cardiovascular events. Second, for each of
the individual outcomes that comprised the composite
cardiovascular event end point, we repeated all of the
analyses described above and found that IDH according
to 24-hour ABPM criteria (by either guideline) was also
not associated with any of these individual outcomes

Multivariable-Adjusted HR in Relation to Hypertension Categories by Nighttime BP
Total mortality (n=2836)

Characteristic

HR (95% CI)

CV event (n=2049)
P value

HR (95% CI)

P value

2017 AHA/ACC criteria
Normotensive (n=4766)

Reference

Isolated diastolic (n=772)

0.99 (0.81–1.21)

0.94

Reference
1.15 (0.92–1.45)

0.22

Isolated systolic (n=1542)

1.14 (1.02–1.27)

0.025

1.35 (1.18–1.55)

<0.001

Combined (n=4055)

1.28 (1.17–1.40)

<0.001

1.62 (1.45–1.80)

<0.001

2018 ESC criteria
Normotensive (n=7362)

Reference

Isolated diastolic (n=834)

1.08 (0.91–1.28)

0.38

Reference
1.12 (0.92–1.36)

0.26

Isolated systolic (n=979)

1.29 (1.15–1.43)

<0.001

1.44 (1.36–1.64)

<0.001

Combined (n=1960)

1.43 (1.31–1.57)

<0.001

1.76 (1.58–1.96)

<0.001

The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC definitions.
Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those
with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated systolic and diastolic hypertension refers to those with
only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted
for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history
of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood
pressure; CV, cardiovascular; ESC, European Society of Cardiology; and HR, hazard ratio.
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in isolation (Tables S7 and S8). Finally, third, analyses
among the 9844 participants without a baseline history
of cardiovascular disease produced consistent results
(Tables S9 and S10).

Analyses Stratified by Age and Sex
After stratification of the whole IDACO cohort into participants younger than 50 and participants of 50 years
or older, there was evidence for higher crude rates of
cardiovascular events among younger persons with IDH
using 2017 ACC/AHA criteria (3.71 per 1000 personyears) compared with younger persons with normal BP
(1.08 per 1000 person-years). By contrast, crude cardiovascular event rates among those aged 50 or more
appeared lower in the IDH subgroup versus normotension (Table S11).
In adjusted Cox models, there was a statistically significant 3-fold increase in adjusted relative risk for cardiovascular events among IDACO participants younger
than 50 who had IDH on 24-hour ABPM by 2017
ACC/AHA criteria, relative to young participants with
normotension (Table 4). Furthermore, there was strong
evidence of effect modification on the basis of age (P
interaction <0.001) and IDACO participants 50 years or
older with IDH had no excess cardiovascular risk compared to normotension. There was also a suggestion of
effect modification by age on the association between
IDH using the 2018 ESC criteria and cardiovascular
events; with marginal evidence for higher risk in younger
adults than older adults (P interaction =0.06). In contrast to cardiovascular events, IDH on 24-hour ABPM
(either by 2017 ACC/AHA or by 2018 ESC criteria)
was not significantly associated with mortality at any age
Table 4.

and there was no evidence of interaction on the basis
of age (Table 4). Similarly, for both the 2018 ESC or
2017 ACC/AHA criteria, the risks of total mortality and
cardiovascular events associated with IDH were similar
among men and women in the whole IDACO cohort (P
interaction =0.10, Tables S12 and S13).

DISCUSSION
In this international study of adults with 24-hour ABPM
recordings, 2 interesting and novel findings become evident. First, we found no association of IDH, as defined by
the 2017 ACC/AHA guideline and using 24-hour ABPM
readings, with adverse outcomes in the sample overall. By
contrast and concordant with prior IDACO reports,18 IDH
on 24-hour ABPM as defined by the 2018 ESC guideline was associated with cardiovascular events, although
not with death. The second observation, which addresses
an issue of controversy12, was that after stratifying the
study sample by age, IDH on 24-hour ABPM was associated with increased risk for cardiovascular events (both
for the 2017 ACC/AHA and the 2018 ESC definitions
of IDH) among participants younger than 50 years only.

ACC/AHA Versus ESC Definitions of IDH
Among Adults of All Ages
The first main finding from this IDACO report is consistent with prior research.5,11 By using 24-hour and
nocturnal ABPM recordings, the current results are an
important validation of the report by McEvoy et al,5 which
analyzed adults of all ages participating in a number of
US cohorts who had BP values collected at a single
point in time as part of a research study visit. The IDACO

Multivariable-Adjusted HR in Relation to Hypertension Categories After Stratification by Age
Total mortality

Pint

Age<50
Characteristic

HR (95% CI)

Age≥50
P value

CV events

Pint

Age<50

HR (95% CI)

P value

HR (95% CI)

Age≥50
P value

HR (95% CI)

P value

2017 AHA/ACC criteria
Normotensive

Reference

Isolated diastolic

1.66 (0.96–2.86)

0.068

Reference
0.91 (0.75–1.10)

0.31

0.076

Reference
2.87 (1.72–4.80)

<0.001

Reference
0.98 (0.78–1.23)

0.87

<0.001

Isolated systolic

0.68 (0.21–2.20)

0.52

1.14 (1.03–1.28)

0.015

0.28

0.74 (0.22–2.43)

0.62

1.33 (1.17–1.52)

<0.001

0.45

Combined

2.08 (1.33–3.25)

0.0013

1.33 (1.21–1.46)

<0.001

0.15

2.39 (1.47–3.89)

<0.001

1.68 (1.50–1.88)

<0.001

0.092

ESC 2018 criteria
Normotensive

Reference

Isolated diastolic

1.82 (0.93–3.57)

0.080

Reference
0.91 (0.75–1.10)

0.22

0.31

Reference
2.41 (1.30–4.45)

0.0052

Reference
1.31 (0.99–1.72)

0.058

0.058

Isolated systolic

0.98 (0.39–2.46)

0.97

1.36 (1.24–1.49)

<0.001

0.39

1.48 (0.66–3.31)

0.34

1.52 (1.35–1.70)

<0.001

0.76

Combined

2.28 (1.38–3.78)

0.0013

1.37 (1.24–1.51)

<0.001

0.097

2.34 (1.38–4.00)

0.0017

1.82 (1.63–2.04)

<0.001

0.24

The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. Normotension refers to those
with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the
cutoff levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the
normotensive group in the age stratification as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total
cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes. Pint is for the interaction between hypertension classifications and age group.
ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; ESC, European Society of Cardiology; HR,
hazard ratio; and Pint, P interaction.
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ACC/AHA Definition of IDH and Outcomes in
Young Versus Old Adults
The second main finding from this IDACO analysis suggests that, by contrast to adults of all ages, the 2017
ACC/AHA definition of IDH may be a specific prognostically adverse feature in young adults aged <50 years.
This question is important for several reasons. First, IDH
is more common in younger adults,22 and about half of
those newly eligible for a diagnosis of IDH since 2017
ACC/AHA guidelines are aged <50 years.5 Second, the
only prior report suggesting interaction by age in the
association between the 2017 ACC/AHA definition
of IDH and events comprised of routinely collected BP
data from a large clinical registry and may have consequently had methodological biases for the reasons
outlined above.9,10 Prior reports of cohorts with rigorous BP measurements that looked for age interaction
in the association between the 2017 ACC/AHA IDH
definition and events have suggested that young adults
were not at increased risk, although these same cohorts

included few younger adults and so may have been
underpowered.11 Therefore, it has been unclear whether
young adults have increased risk for events when IDH
by the 2017 ACC/AHA definition is ascertained using
research-quality BP measurements.
In IDACO, we found that younger adults with IDH
by the 2017 ACC/AHA definition and measured using
24-hour ABPM did indeed have increased risk for cardiovascular events (but not death). This finding utilizing rigorous ascertainment of BP with ABPM confirms
suggestions from prior studies (which used less valid
routine clinical assessment of BP)9,10 that there is an
age-related interaction in the association between the
2017 ACC/AHA definition of IDH and events, with far
stronger excesses in relative risk among young adults
aged less than 50 years compared with older adults. The
physiological reasons for this age interaction are not fully
known; however, a few considerations are worth noting;
(1) diastolic BP has been shown to have more prognostic significance in the young versus the old18 and (2) the
prevalence of elevated diastolic BP is as low as 10% (or
less) among adults over 70 years,4 and, therefore, some
cases of IDH in older IDACO adults may have been
misclassified due to BP measurement error on both
office and 24-hour ABPM (noting that increased vascular stiffness with aging increases the likelihood of the
fifth Korotkoff sound being absent, which could result
in falsely elevated diastolic BP readings and, therefore,
false positive IDH ascertainments).
Finally, several factors might help to explain why this
IDACO age-stratified finding contrasts with the prior epidemiological studies using research-grade BP measurements,5,11 none of which have found an age interaction
for the 2017 ACC/AHA definition of IDH. First, the very
large IDACO dataset is well powered to test this interaction effect, whereas prior studies may not have been;
second, the IDACO sample is younger on average than
some of the prior analyses5 testing the 2017 ACC/AHA
definition of IDH; and, third, by using 24-hour ABPM
readings, our IDACO data were less likely to include spurious or artifactual readings of elevated diastolic BP that
may be more commonly seen in BP assessments at a
single point in time.

Limitations
This observational analysis has limitations. First, we cannot exclude residual confounding, including but not limited to lipid-lowering and antiplatelet therapies. Second,
24-hour BP and antihypertensive drug treatment status
were only recorded at baseline and could therefore not
be adjusted for as a time-dependent covariables. Furthermore, our sensitivity analysis excluding persons on
antihypertensives at baseline may have included some
persons subsequently started on therapy. Third, our prespecified adjustment model did not control for baseline
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results presented here also align with findings from
the UK Biobank.11 In all of these reports, there was no
excess cardiovascular risk associated with IDH by the
2017 ACC/AHA definition when all participants, irrespective of age, were included in analyses. An advantage
of our IDACO data is that the use of 24-hour ABPM
values allows for a more precise measurement of the
IDH exposure than has previously been possible, even
allowing for the rigorous methods used to record BP in
the prior analyses.5,11
Therefore, these IDACO data challenge prior reports
from four large clinical registries, which have suggested
a modest increase in adjusted risk for IDH by the 2017
ACC/AHA definition among adults of all ages.4,10,19,20
These registries studied adults attending routine clinical
care visits (thereby introducing the possibility of some
confounding by indication) and who had routine, nonstandardized, clinical measurement, and documentation
of BP. It is known that routine clinical measurement of
BP and recording in electronic health records are not
as accurate as standardized assessments undertaken as
part of rigorous epidemiological studies like IDACO (this
is true in particular for diastolic BP).21
This IDACO analysis also confirms data from UK Biobank,11 and elsewhere,8 demonstrating an increased risk
for events among adults of all ages with IDH as defined
by the 2018 ESC criteria. The apparent conflict between
the 2017 ACC/AHA and 2018 ESC definitions of IDH
can be explained by the former definition requiring a
diastolic BP ≥80 mm Hg, whereas the latter requires a
diastolic BP ≥90 mm Hg. This suggests that, among all
adults with controlled systolic BP, risk for cardiovascular
events is low when diastolic BP is between 80 and 89
mm Hg but increases once diastolic BP is ≥90 mm Hg.
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EPIDEMIOLOGY/POPULATION
SCIENCE

McEvoy et al

Age-Stratified Risk of Isolated Diastolic Hypertension

heart rate; however, in further sensitivity analyses adding heart rate to this model, the results remained quantitatively and qualitatively very similar (data not shown).
Fourth, there might be misclassification bias in the
assessment of the cardiovascular study end points.23
However, all-cause mortality does not require any adjudication and is therefore not subject to this bias. Fifth,
diastolic BP levels as assessed using automated oscillometric ABPM devices can sometimes overestimate true
diastolic BP as measured using intra-arterial transducers. In addition, although categorical analyses of diastolic
BP have implications for clinical care (given the use of
specific BP thresholds to define hypertension), it is also
worth noting that BP is a continuous pathophysiologic
exposure variable. Sixth, our findings of interaction by
age could represent the play of chance; however, they
were prespecified and the highly significant P interaction values also make this less likely, as do prior data
from registry studies suggesting significant interaction
by age on the association between IDH (by both 2017
ACC/AHA and by 2018 ESC criteria) and cardiovascular events.10 Finally, eighth, no Black participants were
included in the IDACO database, and caution should be
taken when extrapolating our results to races and ethnicities that were not included.
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